Jason Luke, MD: Durability of a Response to Targeted Therapy Combination
How durable of a response to the targeted therapy combination would you anticipate for this patient, based on LDH levels, age, and sites of disease?
CASE: Metastatic Melanoma
Charles, a 62-year-old Caucasian landscaper, presented to his primary care physician with fatigue, dyspnea upon exertion, and a nonproductive cough that has lasted for 6 to 8 weeks. .
- Following a medical examination, a suspicious mole was biopsied, which resulted in a diagnosis of melanoma.
- Genetic testing revealed aBRAFV600K mutation
- PET/CT scan shows metastases to the lung and a soft tissue nodule in the liver (1.4 cm x 1.1 cm)
- LDH levels and liver function test results were normal
- The patient’s ECOG performance status was 1
Treatment was initiated with the combination of BRAF and MEK inhibitors.
Atlas Examines Tolerability of Hedgehog Pathway Inhibitors and Transition to IO in mBCC
October 16th 2024During a Case-Based Roundtable® event, Jennifer L. Atlas, MD, discussed treatment for a patient with basal cell carcinoma who reported challenging adverse events with hedgehog pathway inhibitor.
Read More
RELATIVITY-047 vs CheckMate 067 Matched Cohorts in Melanoma Show Similar Efficacy
October 10th 2024During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the indirect comparison of ipilimumab plus nivolumab and nivolumab/relatlimab in advanced melanoma in the second article of a 2-part series.
Read More
